Terms: = Thyroid cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR
24 results:
1. "Examining the link between tooth agenesis and papillary thyroid cancer: is there a risk factor?" Observational study.
Matošić Ž; Šimunović L; Jukić T; Granić R; Meštrović S
Prog Orthod; 2024 Mar; 25(1):12. PubMed ID: 38523193
[TBL] [Abstract] [Full Text] [Related]
2. Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary thyroid Carcinoma.
Hadoux J; Al Ghuzlan A; Lamartina L; Bani MA; Moog S; Attard M; Scoazec JY; Hartl D; Aldea M; Friboulet L; Jules-Clement G; Italiano A; Besse B; Lacroix L; Baudin E
JCO Precis Oncol; 2023 Sep; 7():e2300053. PubMed ID: 38127829
[TBL] [Abstract] [Full Text] [Related]
3. Mesonephric-like adenocarcinoma of the ovary with squamoid morular metaplasia, aberrant β-catenin expression, and concurrent fgfr2 and CTNNB1 mutations: a case report.
Xu J; Park KJ; Rehrauer WM; Weisman PS
Virchows Arch; 2024 Jan; 484(1):147-150. PubMed ID: 36856760
[TBL] [Abstract] [Full Text] [Related]
4. Activation of fgfr2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy.
Lei JH; Lee MH; Miao K; Huang Z; Yao Z; Zhang A; Xu J; Zhao M; Huang Z; Zhang X; Chen S; Jiaying NG; Feng Y; Xing F; Chen P; Sun H; Chen Q; Xiang T; Chen L; Xu X; Deng CX
Adv Sci (Weinh); 2021 Nov; 8(21):e2100974. PubMed ID: 34514747
[TBL] [Abstract] [Full Text] [Related]
5. The Integrated Analyses of Driver Genes Identify Key Biomarkers in thyroid cancer.
Xu Q; Song A; Xie Q
Technol Cancer Res Treat; 2020; 19():1533033820940440. PubMed ID: 32812852
[TBL] [Abstract] [Full Text] [Related]
6. MicroRNA-1266 suppresses papillary thyroid carcinoma cell metastasis and growth via targeting fgfr2.
Fu YT; Zheng HB; Zhang DQ; Zhou L; Sun H
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3430-3438. PubMed ID: 29917195
[TBL] [Abstract] [Full Text] [Related]
7. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract] [Full Text] [Related]
8. Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.
Beltrami CM; Dos Reis MB; Barros-Filho MC; Marchi FA; Kuasne H; Pinto CAL; Ambatipudi S; Herceg Z; Kowalski LP; Rogatto SR
Clin Epigenetics; 2017; 9():45. PubMed ID: 28469731
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.
Tiedje V; Ting S; Walter RF; Herold T; Worm K; Badziong J; Zwanziger D; Schmid KW; Führer D
Eur J Endocrinol; 2016 Sep; 175(3):173-80. PubMed ID: 27283290
[TBL] [Abstract] [Full Text] [Related]
10. The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.
Kasaian K; Wiseman SM; Walker BA; Schein JE; Zhao Y; Hirst M; Moore RA; Mungall AJ; Marra MA; Jones SJ
BMC Cancer; 2015 Dec; 15():984. PubMed ID: 26680454
[TBL] [Abstract] [Full Text] [Related]
11. Anchored multiplex PCR for targeted next-generation sequencing.
Zheng Z; Liebers M; Zhelyazkova B; Cao Y; Panditi D; Lynch KD; Chen J; Robinson HE; Shim HS; Chmielecki J; Pao W; Engelman JA; Iafrate AJ; Le LP
Nat Med; 2014 Dec; 20(12):1479-84. PubMed ID: 25384085
[TBL] [Abstract] [Full Text] [Related]
12. Potential prognostic and diagnostic application of a novel monoclonal antibody against keratinocyte growth factor receptor.
Ceccarelli S; Bei R; Vescarelli E; D'Amici S; di Gioia C; Modesti A; Romano F; Redler A; Marchese C; Angeloni A
Mol Biotechnol; 2014 Oct; 56(10):939-52. PubMed ID: 24899248
[TBL] [Abstract] [Full Text] [Related]
13. Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours.
Parker BC; Engels M; Annala M; Zhang W
J Pathol; 2014 Jan; 232(1):4-15. PubMed ID: 24588013
[TBL] [Abstract] [Full Text] [Related]
14. Fibroblast growth factor receptor-2 expression in thyroid tumor progression: potential diagnostic application.
Redler A; Di Rocco G; Giannotti D; Frezzotti F; Bernieri MG; Ceccarelli S; D'Amici S; Vescarelli E; Mitterhofer AP; Angeloni A; Marchese C
PLoS One; 2013; 8(8):e72224. PubMed ID: 23977259
[TBL] [Abstract] [Full Text] [Related]
15. Identification of targetable FGFR gene fusions in diverse cancers.
Wu YM; Su F; Kalyana-Sundaram S; Khazanov N; Ateeq B; Cao X; Lonigro RJ; Vats P; Wang R; Lin SF; Cheng AJ; Kunju LP; Siddiqui J; Tomlins SA; Wyngaard P; Sadis S; Roychowdhury S; Hussain MH; Feng FY; Zalupski MM; Talpaz M; Pienta KJ; Rhodes DR; Robinson DR; Chinnaiyan AM
Cancer Discov; 2013 Jun; 3(6):636-47. PubMed ID: 23558953
[TBL] [Abstract] [Full Text] [Related]
16. fgfr2 isoforms support epithelial-stromal interactions in thyroid cancer progression.
Guo M; Liu W; Serra S; Asa SL; Ezzat S
Cancer Res; 2012 Apr; 72(8):2017-27. PubMed ID: 22345151
[TBL] [Abstract] [Full Text] [Related]
17. Substernal goiters: incidence, surgical approach, and complications in a tertiary care referral center.
Raffaelli M; De Crea C; Ronti S; Bellantone R; Lombardi CP
Head Neck; 2011 Oct; 33(10):1420-5. PubMed ID: 21928414
[TBL] [Abstract] [Full Text] [Related]
18. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.
Beadling C; Heinrich MC; Warrick A; Forbes EM; Nelson D; Justusson E; Levine J; Neff TL; Patterson J; Presnell A; McKinley A; Winter LJ; Dewey C; Harlow A; Barney O; Druker BJ; Schuff KG; Corless CL
J Mol Diagn; 2011 Sep; 13(5):504-13. PubMed ID: 21726664
[TBL] [Abstract] [Full Text] [Related]
19. Correlating global gene regulation to angiogenesis in the developing chick extra-embryonic vascular system.
Javerzat S; Franco M; Herbert J; Platonova N; Peille AL; Pantesco V; De Vos J; Assou S; Bicknell R; Bikfalvi A; Hagedorn M
PLoS One; 2009 Nov; 4(11):e7856. PubMed ID: 19924294
[TBL] [Abstract] [Full Text] [Related]
20. Identification of borderline thyroid tumors by gene expression array analysis.
Arora N; Scognamiglio T; Lubitz CC; Moo TA; Kato MA; Zhu B; Zarnegar R; Chen YT; Fahey TJ
Cancer; 2009 Dec; 115(23):5421-31. PubMed ID: 19658182
[TBL] [Abstract] [Full Text] [Related]
[Next]
